ClintDanielKingsleyMDFACP

PubMed

• 27 citations
  Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung C...
  Heather A. Wakelee, Zanete Zvirbule, Filippo de Braud, C. Daniel Kingsley, Tarek Mekhail
  Clinical Lung Cancer. 2017-01-01
• 6 citations
  Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer
  Johanna C. Bendell, Heinz-Josef Lenz, Theresa Ryan, Bassel F. El-Rayes, John L. Marshall
  Investigational New Drugs. 2014-04-03
• 62 citations
  Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
  Jennifer R. Brown, Susan O'Brien, C. Daniel Kingsley, Herbert Eradat, John M. Pagel
  Blood. 2015-04-30

Books/Book Chapters

• The Chemotherapy Sourcebook 
  Chapter: Hypersensitivity Reactions 
  Page 160 - 185Kingsley CDEditors: Perry MC.Lippincott Williams & Wilkins, PhiladelphiaEdition 5,2012
• Cancer: Principles and Practice of Oncology Review 
  Chapter: Paraneoplastic Syndromes 
  Page 517 - 524Kingsley CD and Perry MCEditors: Govindan R.Lippincott Williams & Wilkins, PhiladelphiaEdition 3,2012
• Internal Medicine: Just the Facts 
  Chapter: Cancer of Unknown Primary 
  Page 499 - 504Kingsley CDEditors: Schmitz PG, Martin KJ, and Miller DD.McGraw-Hill, New YorkEdition 1,2008
• Internal Medicine: Just the Facts 
  Chapter: Oncologic Emergencies 
  Page 497 - 498Kingsley CDEditors: Schmitz PG, Martin KJ, and Miller DD.McGraw-Hill, New YorkEdition 1,2008
• Internal Medicine: Just the Facts 
  Chapter: White Cell Disorders 
  Page 377 - 380Kingsley CDEditors: Schmitz PG, Martin KJ, and Miller DD.McGraw-Hill, New YorkEdition 1,2008
• Cancer: Principles and Practice of Oncology Review 
  Chapter: Paraneoplastic Syndromes 
  Page 449 - 455Kingsley CD and Perry MC.Editors: Govindan R. Lippincott Williams & Wilkins, PhiladelphiaEdition 2,2008
• The Chemotherapy Sourcebook 
  Chapter: Hypersensitivity Reactions 
  Page 152 - 173Kingsley CD, and Weiss RBEditors: Perry MC.Lippincott Williams & Wilkins, PhiladelphiaEdition 4,2007
• Join now to see all

Abstracts/Posters

• Efficacy and safety of onartuzumab in combination with first-line bevacizumab or pemetrexed based chemotherapy regimens in advanced non-squamous non-small-cell lung ca...
  Wakelee H, Zvirbule Z, DeBraud F, Kingsley CD, Mekhail T, Schutte W, Lena H, Lawler W, Braiteh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S, 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Poster, 10/1/2014
• Safety and Efficacy of Obinutuzumab (GA101) with Fludarabine/Cyclophosphamide (G-FC) or Bendamustine (G-B)in the Initial Therapy of Patients with Chronic Lymphocytic L...
  Brown JR, O’Brien S, Kingsley CD, Eradat H, Pagel JM, Lymph J, Hirata J, Kipps TJ., ASH Annual Meeting, Abstract 523 & Oral Presentation 642, 12/1/2013
• Acute Diastolic Heart Failure Secondary to Severe Vitamin B12 Deficiency
  Huggins J, Kingsley CD, and Ibrahim F, Alabama ACP Annual Meeting, Poster, 5/1/2010
• The effects of race on stage of presentation and survival for patients with adenocarcinoma of the colon/rectum at an urban teaching facility.
  Kingsley CD, Wan JY, Patterson KS, Wright K, Donnelly L, and Adler P, ASCO Annual Meeting, Abstract number 3637, 6/1/2004
• Join now to see all